HAM
ACAD icon

Highstreet Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Highstreet Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-34
Closed -$1K – 420
2019
Q2 		$1K Buy
+34
New +$869 ﹤0.01% 387

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Highstreet Asset Management's ACAD Position: Q3 2019 in Review

Highstreet Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 34 shares — an estimated $1K sold.

Highstreet Asset Management first reported a position in ACAD in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

  • Highstreet Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Highstreet Asset Management sold 34 Acadia Pharmaceuticals shares in Q3 2019, an estimated $1K.
  • Highstreet Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Highstreet Asset Management's Acadia Pharmaceuticals position peaked at $1K in Q2 2019.
  • 231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Highstreet Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.